SANTA FE, NM / ACCESSWIRE / February 10, 2022 / Sigma Labs, Inc. (NASDAQ: SGLB) (the "Company"), a leading developer of quality assurance software to the commercial 3D printing industry, announced today that the Company's warrants to purchase common stock issued on February 21, 2017 (NASDAQ: SGLBW) (the "Warrants") will expire in accordance with their terms as of 5:00 p.m. EST, on February 22, 2022. The Company is informed by the Nasdaq Stock Market LLC ("Nasdaq") that trading of the Warrants on Nasdaq will be suspended on February 17, 2022. The exercise price for one share of the Company's common stock under the Warrants is $40.00. On February 9, 2022, the last reported sale price of the Company's common stock was $2.42 per share.
The Company also is informed that Nasdaq intends to file a Form 25 on behalf of the Company with the Securities and Exchange Commission on February 17, 2022 to effect the delisting of the Warrants from Nasdaq and the deregistration of the Warrants under Section 12(b) of the Securities Exchange Act of 1934, as amended.
The listing of the Company's common stock (NASDAQ: SGLB) will not be affected by the expiration and delisting of the Warrants.
About Sigma Labs
Sigma Labs Inc. is a leading provider of in-process quality assurance (IPQA") software to the additive manufacturing industry. Sigma Labs specializes in the development and commercialization of real-time monitoring and analytics solutions known as PrintRite3D for 3D metal and polymer advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process, enabling significant cost-savings and production efficiencies. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of industrial 3D printing. For more information, please visit www.sigmalabsinc.com.
Contacts:
Investor Contact: Chris TysonExecutive Vice President MZ Group - MZ North America949-491-8235SGLB@mzgroup.uswww.mzgroup.us
Company Contact:Steven GerstenSigma Internal IR813-334-9745investors@sigmalabsinc.com
SOURCE: Sigma Labs, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。